echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Carry out special rectification of production of Chinese Herbal Pieces in many places, and carry out spot check in the province

    Carry out special rectification of production of Chinese Herbal Pieces in many places, and carry out spot check in the province

    • Last Update: 2019-08-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [industry trends of pharmaceutical network] recently, Fujian food and Drug Administration announced the special inspection and treatment of the centralized quality control (production link) of Chinese Herbal Pieces in 2019 According to the centralized treatment of Chinese herbal pieces from April to July 2019, it was found that 15 pharmaceutical enterprises failed in the sampling inspection of 15 batches of Chinese herbal pieces, one of them was withdrawn GMP certificate, and the other 14 were ordered to rectify Among them, the Chinese herbal pieces produced by enterprises were ordered to rectify due to 11 defects According to the relevant person in charge of the enterprise, the 11 defects pointed out in the publicity do not only refer to the problems of the drug itself, but also include many aspects, including the production link of the drug, whether the operation of the workers is standardized, whether the inspection meets the relevant standards, and whether the company's audit is compliant, etc At present, the batch of drugs has been rectified and can be produced and sold normally In addition to Fujian Province, many places have carried out special rectification of the production of Chinese herbal pieces, and issued work implementation plans to effectively guarantee the development of higher quality Chinese Herbal Pieces Market Shandong: the sampling plan for 3000 batches of Chinese herbal pieces came from Shandong Province In 2018, Shandong Province printed and distributed the implementation plan for the centralized treatment of the quality of Chinese herbal pieces It is required to arrange another 3000 batches of Chinese Herbal Pieces in 2019 based on the careful implementation of the sampling plan in 2018 Shanxi Province: held the quality and safety commitment meeting for the production and operation enterprises of Chinese herbal pieces On August 15, Shanxi Province convened the quality and safety commitment meeting for the production and operation enterprises of Chinese Herbal Pieces in Taiyuan The legal representatives of 24 enterprises producing Chinese herbal pieces and 270 pharmaceutical trading enterprises attended the meeting At the meeting, it was required that all production and operation enterprises should fulfill the four requirements, put drug quality and safety first, establish and improve the quality management system and ensure normal operation, assume the legal responsibility for drug quality and safety, and implement the main responsibility for quality and safety It is understood that in view of the outstanding problems existing in the market of Chinese herbal pieces, Shanxi provincial drug administration has organized a one-year centralized treatment of Chinese Herbal Pieces in the whole province Heilongjiang: strictly check the illegal behaviors in circulation and use On April 26, Heilongjiang Provincial Drug Administration issued the work plan of drug circulation supervision and inspection in 2019, which requires to continue to carry out the centralized rectification of the quality of Chinese herbal pieces According to the requirements of the implementation plan for the centralized quality control of Chinese Herbal Pieces in Heilongjiang Province, we will strictly investigate and punish the illegal behaviors in the circulation and use of Chinese herbal pieces Hubei: targeted supervision On April 30, Hubei Provincial Drug Administration issued a notice saying that the centralized management of the quality of Chinese herbal pieces should be included in the important agenda of drug safety work, and the targeted special management work should be carried out to achieve supervision The municipal and prefectural market supervision bureaus shall, according to the relevant requirements, report to the provincial food and drug administration the progress of centralized rectification in the last month before the 10th of each month This work in Hubei Province is in line with the direction of the notice on printing and distributing the work plan for centralized quality control of Chinese Herbal Pieces issued by the State Food and Drug Administration in 2018 It is clear in the notice that one-year centralized remediation will be carried out from October 2018 to September 2019 Each province must complete the summary of the rectification work before the end of October 2019 and submit it to the National Bureau In addition to the above areas, Sichuan, Shaanxi, Liaoning, Hunan, Gansu, Anhui and other provinces have also successively issued plans for the centralized quality control of Chinese herbal pieces.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.